

Table 2. Clinicopathologic data of women with serous ovarian carcinoma showing mild to moderate nuclear atypia

Intra-tumoral budding	Age	FIGO Stage	CA125 before treatment	CA125 after 3 cycles of chemotherapy	Architectural grade	Nuclear grade	Mitoses*	LVSI	Lymph node metastasis	Survival (months)	Status
Absent											
	56	IC1	132.5	12.2	1	1	6	-	-	52	NED
	77	IIB	574.0	10.0	1	2	21	-	-	91	NED
	61	IIIA2	8367.0	16.7	1	2	8	-	+	68	AWD
	66	IIB	136.7	19.3	1	2	12	-	-	75	DOD
	62	IIIC	4789.9	7.3	2	2	18	+	NA	74	DOD
Present											
	48	IVB	276.1	11.7	3	2	8	-	+	47	NED
	77	IIIC	12000.0	28.4	1	1	32	+	NA	36	DOC
	50	IIIC	7270.0	NA	1	2	14	+	+	11	DOD
After neoadjuvant chemotherapy											
	53	IIIC	558.7	40.7	2	2	8	+	+	50	DOD
	55	IIIB	9327.1	116.8	1	2	5	+	-	39	DOD
	70	IVB	336.6	29.1	1	2	10	-	NA	52	DOD

\*X10high power fields, LVSI; lymphovascular space invasion, NA: not applicable

Lymphovascular space invasion and lymph node metastasis were classified as either present (+) or absent (-).

Patient status defined as DOD (dead of disease), NED (no evidence of disease), AWD (alive with disease), and DOC (death from other causes).